Video

Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © nimito - stock.adobe.com
Image Credit: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
Image Credit: © sofiko14 - stock.adobe.com
Image Credit: © hamad - stock.adobe.com
Related Content
Nurse preparing dextrose infusion | Image Credit: © Sherry Young - stock.adobe.com
January 20th 2025

Managing Cancer Treatment Amid a Nationwide IV Fluid Shortage

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Leukemia blood cells medical science background concept.
January 17th 2025

IVIG Prophylaxis Significantly Reduces Hospital Admissions for Fever in Pediatrics With ALL

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
September 26th 2022

Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia

Cancer cells depicted as pink bubbles.
January 17th 2025

FDA Approves Acalabrutinib With Bendamustine, Rituximab For Patients With Previously Untreated Mantle Cell Lymphoma

Luke Halpern, Assistant Editor
Bispecific antibodies | Image Credit: © Galina - stock.adobe.com
January 16th 2025

Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor